Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 550Head and Neck Neoplasms 490Carcinoma, Non-Small-Cell Lung 338Melanoma 217Colorectal Neoplasms 206Ovarian Neoplasms 174Neoplasms 171Breast Neoplasms 168Stomach Neoplasms 141Carcinoma, Renal Cell 133Uterine Cervical Neoplasms 129Neoplasm Metastasis 129Triple Negative Breast Neoplasms 125Lung Neoplasms 118Pancreatic Neoplasms 117Esophageal Neoplasms 107Thyroid Neoplasms 95Endometrial Neoplasms 93Urinary Bladder Neoplasms 92Prostatic Neoplasms 88Sarcoma 81Carcinoma, Squamous Cell 81Carcinoma, Transitional Cell 75Small Cell Lung Carcinoma 74Carcinoma, Hepatocellular 65Recurrence 53Nasopharyngeal Carcinoma 52Carcinoma 47Colonic Neoplasms 46Cholangiocarcinoma 43

Interventions

spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Disorders of Sex Development × Head & Neck × Clear all
NCT02605967 2022-02-10

Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Novartis

Phase 2 Completed
122 enrolled 28 charts
Head & Neck

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Recurrence, Disorders of Sex Development

Data powered by HemOnc (CC BY 4.0) Colophon âš¡